rs1555791268
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 15 ACMG points: 15P and 0B. PM1PM2PP2PP3_ModeratePP5_Very_Strong
The NM_014225.6(PPP2R1A):c.656C>T(p.Ser219Leu) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: not found (cov: 32)
Exomes 𝑓: 0.0 ( 0 hom. )
Failed GnomAD Quality Control
Consequence
PPP2R1A
NM_014225.6 missense
NM_014225.6 missense
Scores
13
4
2
Clinical Significance
Conservation
PhyloP100: 4.11
Genes affected
PPP2R1A (HGNC:9302): (protein phosphatase 2 scaffold subunit Aalpha) This gene encodes a constant regulatory subunit of protein phosphatase 2. Protein phosphatase 2 is one of the four major Ser/Thr phosphatases, and it is implicated in the negative control of cell growth and division. It consists of a common heteromeric core enzyme, which is composed of a catalytic subunit and a constant regulatory subunit, that associates with a variety of regulatory subunits. The constant regulatory subunit A serves as a scaffolding molecule to coordinate the assembly of the catalytic subunit and a variable regulatory B subunit. This gene encodes an alpha isoform of the constant regulatory subunit A. Alternatively spliced transcript variants have been described. [provided by RefSeq, Apr 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 15 ACMG points.
PM1
In a region_of_interest SV40 small T antigen binding (size 154) in uniprot entity 2AAA_HUMAN there are 4 pathogenic changes around while only 0 benign (100%) in NM_014225.6
PM2
Very rare variant in population databases, with high coverage;
PP2
Missense variant in gene, where missense usually causes diseases (based on misZ statistic), PPP2R1A. . Gene score misZ 4.4565 (greater than the threshold 3.09). Trascript score misZ 5.4176 (greater than threshold 3.09). GenCC has associacion of gene with intellectual disability, autosomal dominant 40, Houge-Janssens syndrome 2, complex neurodevelopmental disorder.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.863
PP5
Variant 19-52212959-C-T is Pathogenic according to our data. Variant chr19-52212959-C-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 521503.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PPP2R1A | NM_014225.6 | c.656C>T | p.Ser219Leu | missense_variant | 6/15 | ENST00000322088.11 | NP_055040.2 | |
PPP2R1A | NM_001363656.2 | c.119C>T | p.Ser40Leu | missense_variant | 6/15 | NP_001350585.1 | ||
PPP2R1A | NR_033500.2 | n.600C>T | non_coding_transcript_exon_variant | 5/14 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PPP2R1A | ENST00000322088.11 | c.656C>T | p.Ser219Leu | missense_variant | 6/15 | 1 | NM_014225.6 | ENSP00000324804.6 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
GnomAD4 exome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 1442742Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 716340
GnomAD4 exome
Data not reliable, filtered out with message: AC0
AF:
AC:
0
AN:
1442742
Hom.:
Cov.:
31
AF XY:
AC XY:
0
AN XY:
716340
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:13Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Houge-Janssens syndrome 2 Pathogenic:8
Likely pathogenic, criteria provided, single submitter | clinical testing | Equipe Genetique des Anomalies du Developpement, Université de Bourgogne | Jan 01, 2016 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | 3billion | Jan 03, 2022 | he variant has been previously reported as de novo in a similarly affected individual (PMID:29100083, PS2_S). Same nucleotide change resulting in same amino acid change has been previously reported to be associated with PPP2R1A related disorder (PMID:29100083, PS1_P). A missense variant is a common mechanism associated with Mental retardation (PP2_P). It is not observed in the gnomAD v2.1.1 dataset (PM2_M). TTherefore, this variant is classified as likely pathogenic according to the recommendation of ACMG/AMP guideline. - |
Pathogenic, criteria provided, single submitter | research | Duke University Health System Sequencing Clinic, Duke University Health System | Apr 20, 2023 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Mar 01, 2021 | This variant was identified as de novo (maternity and paternity confirmed). - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Juno Genomics, Hangzhou Juno Genomics, Inc | - | PM2+PS2 - |
Pathogenic, criteria provided, single submitter | research | HudsonAlpha Institute for Biotechnology, HudsonAlpha Institute for Biotechnology | Feb 16, 2024 | ACMG codes:PS2, PS4, PM2, PP2, PP3 - |
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Dec 10, 2021 | The PPP2R1A c.656C>T (p.Ser219Leu) missense variant results in the substitution of serine at amino acid position 219 with leucine. This variant has been reported in a de novo heterozygous state in five individuals with PPP2R1A-related neurodevelopmental disorder (Hamdan et al. 2017; Zhang et al. 2020; Lenaerts et al. 2021). This variant is not found in version 2.1.1 or version 3.1.2 of the Genome Aggregation Database. Functional studies in HEK293 cells by Lenaerts et al. (2021) demonstrated that the c.656C>T variant showed near complete loss of binding of the B55α and B56β regulatory subunits, while binding to PP2A-C subunit was reduced by about 50%. Based on the available evidence, the c.656C>T (p.Ser219Leu) variant is classified as pathogenic for PPP2R1A-related neurodevelopmental disorder. - |
Pathogenic, no assertion criteria provided | clinical testing | Génétique des Maladies du Développement, Hospices Civils de Lyon | - | - - |
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 14, 2024 | This sequence change replaces serine, which is neutral and polar, with leucine, which is neutral and non-polar, at codon 219 of the PPP2R1A protein (p.Ser219Leu). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with PPP2R1A-related conditions (PMID: 29100083, 31531803, 33106617; Invitae). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 521503). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt PPP2R1A protein function with a positive predictive value of 80%. For these reasons, this variant has been classified as Pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jun 01, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Nov 15, 2021 | Not observed in large population cohorts (Lek et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; In-silico analysis is inconclusive as to whether the variant alters gene splicing. In the absence of RNA/functional studies, the actual effect of this sequence change is unknown.; This variant is associated with the following publications: (PMID: 29100083, 26920370, 31531803) - |
PPP2R1A-related disorder Pathogenic:1Other:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 03, 2024 | The PPP2R1A c.656C>T variant is predicted to result in the amino acid substitution p.Ser219Leu. This variant occurred de novo in two patients with developmental and epileptic encephalopathy (Hamdan et al. 2017. PubMed ID: 29100083; Zhang et al. 2019. PubMed ID: 31531803). Additionally, de novo missense variation is a known mechanism of PPP2R1A-related disease (McRae et al. 2017. PubMed ID: 28135719; Houge et al. 2015. PubMed ID: 26168268). This variant has not been reported in a large population database, indicating this variant is rare. Based on the available evidence, we interpret this variant as pathogenic. - |
not provided, no classification provided | phenotyping only | GenomeConnect - Brain Gene Registry | - | Variant classified as Pathogenic and reported on 01-08-2020 by GeneDx. Assertions are reported exactly as they appear on the patient provided laboratory report. GenomeConnect does not attempt to reinterpret the variant. The IDDRC-CTSA National Brain Gene Registry (BGR) is a study funded by the U.S. National Center for Advancing Translational Sciences (NCATS) and includes 13 Intellectual and Developmental Disability Research Center (IDDRC) institutions. The study is led by Principal Investigator Dr. Philip Payne from Washington University. The BGR is a data commons of gene variants paired with subject clinical information. This database helps scientists learn more about genetic changes and their impact on the brain and behavior. Participation in the Brain Gene Registry requires participation in GenomeConnect. More information about the Brain Gene Registry can be found on the study website - https://braingeneregistry.wustl.edu/. - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 08, 2024 | The c.656C>T (p.S219L) alteration is located in exon 6 (coding exon 6) of the PPP2R1A gene. This alteration results from a C to T substitution at nucleotide position 656, causing the serine (S) at amino acid position 219 to be replaced by a leucine (L). This variant has been determined to be the result of a de novo mutation in multiple individuals with features consistent with PP2R1A-related neurodevelopmental disorder (Hamdan, 2017; Zhang, 2020; Lenaerts, 2020; DECIPHER v.9.32; Ambry internal data). PP2A binding assays demonstrated altered PP2A B-type subunit binding and decreased C subunit binding and a PP2A activity assay demonstrated significantly reduced PP2A activity (Lenaerts, 2020). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. This missense alteration is located in a region that has a low rate of benign missense variation (Lek, 2016; Firth, 2009). The in silico prediction for this alteration is inconclusive. Based on the available evidence, this alteration is classified as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Uncertain
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Pathogenic
D;.;.
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Uncertain
D
LIST_S2
Pathogenic
D;D;D
M_CAP
Uncertain
D
MetaRNN
Pathogenic
D;D;D
MetaSVM
Benign
T
MutationAssessor
Pathogenic
M;.;.
PrimateAI
Pathogenic
D
PROVEAN
Pathogenic
D;.;.
REVEL
Uncertain
Sift
Pathogenic
D;.;.
Sift4G
Pathogenic
D;D;D
Polyphen
D;.;.
Vest4
MutPred
Loss of disorder (P = 0.0233);.;.;
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at